Ophthalmic spray combined preparation for relieving blepharoptosis and red eye

By developing a compound ophthalmic spray preparation, combined with α-adrenaline receptor agonist and other excipients, the problems of low bioavailability and great side effects of traditional eye drops are solved, and the effect of efficient treatment of ptosis and reducing side effects is achieved.

CN119700672APending Publication Date: 2025-03-28LEXENPHARM (SUZHOU) LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202411834445.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-13
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Existing drugs used to treat ptosis often lead to side effects such as conjunctivitis, eye irritation and red eyes, and traditional eye drops have low bioavailability and severe drug loss during administration.

Method used

A compound ophthalmic spray preparation is developed, containing components such as α-adrenergic receptor agonist, sodium hyaluronate, osmotic pressure regulator and thickener. The drug liquid is atomized into small-sized particles through a spray device to spray it on the eye to reduce drug loss and irritation, and to enhance the protection of the eye by adjusting the type and content of auxiliary materials.

Benefits of technology

This preparation can not only effectively treat ptosis, but also significantly reduce side effects such as red eyes, improve the bioavailability of drugs, reduce drug loss and irritation during administration, and enhance eye protection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an ophthalmic spray combined preparation for relieving blepharoptosis or relieving red eyes from blepharoptosis. The ophthalmic spray combined preparation is characterized by comprising the following components in percentage by mass: 0.01-1.15% of an alpha-adrenergic receptor agonist, 0.01-1.15% of an emulsifier, 0.01-1.15% of an emulsifier and the balance of water. 0.1% to 0.3% of sodium hyaluronate; 0.01%-2% of an osmotic pressure regulator; the liquid medicine further comprises a pH buffering agent, wherein the concentration of the pH buffering agent is 0.002 M to 0.16 M; the thickening agent is one or a combination of more of hydroxyethyl cellulose, polyvinyl alcohol and povidone, and the mass percent of the vitamin A derivative and the vitamin E derivative is 0.01%-0.2%. The spray preparation comprises a spraying device, and the spray particle size ranges from 5 mu m to 500 mu m, preferably ranges from 5 mu m to 100 mu m, and more preferably ranges from 10 mu m to 30 mu m.
Need to check novelty before this filing date? Find Prior Art